MART-1-and gp100-expressing and-non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro

Journal of Investigative Dermatology

Volumn 132, Issue 2, 2012, Pages 365-374

  Aris, Mariana ^a,b   Zubieta, Mariana Rodríguez ^a   Colombo, Marina ^a   Arriaga, Juan Martín ^b   Bianchini, Michele ^b   Alperovich, Myriam ^c   Bravo, Alicia I ^d   Barrio, María M ^b   Mordoh, José ^a,b  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^b INSTITUTO ALEXANDER FLEMING   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d Unidad de Inmunopatología   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CD271 ANTIGEN; CELL ANTIGEN; GLYCOPROTEIN GP 100; KI 67 ANTIGEN; MELAN A; MONOPHENOL MONOOXYGENASE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; CYTOLYSIS; CYTOPLASM; CYTOTOXIC LYMPHOCYTE; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; MELANOMA CELL; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION;

EID: 84855961822     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.312     Document Type: Article

References (43)

1. Ballare C, Bravo AI, Sorin I et al. (1991) The expression of progesterone receptors coincides with an arrest of DNA synthesis in human breast cancer. Cancer 67:1352-8
2. Barrio MM, de Motta PT, Kaplan J et al. (2006) A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J Immunother 29:444-54 (Pubitemid 44288957)
3. Benlalam H, Vignard V, Khammari A et al. (2007) Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunol Immunother 56:515-26 (Pubitemid 46204537)
4. Bins A, Mallo H, Sein J et al. (2007) Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients. J Immunother 30:234-9 (Pubitemid 46667803)
5. Boiko AD, Razorenova OV, van de Rijn M et al. (2010) Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466:133-7
6. Boni A, Cogdill AP, Dang P et al. (2010) Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70:5213-9
7. Breart B, Lemaitre F, Celli S et al. (2008) Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest 118:1390-7 (Pubitemid 351500432)
8. Brichard V, Van Pel A, Wolfel T et al. (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489-95 (Pubitemid 23218197)
9. Clark Jr WH, Elder DE, Guerry Dt et al. (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-904 (Pubitemid 20026075)
10. Civenni G, Walter A, Kobert N et al. (2011) Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res 71:3098-109
11. Coulie PG, Brichard V, Van Pel A et al. (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180:35-42 (Pubitemid 24181053)
12. Chen YT, Scanlan MJ, Sahin U et al. (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914-8 (Pubitemid 27113936)
13. De Vries TJ, Fourkour A, Wobbes T et al. (1997) Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 57:3223-9 (Pubitemid 27351739)
14. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471-4
15. Ghannam S, Pene J, Torcy-Moquet G et al. (2010) Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 185:302-12
16. Godet Y, Moreau-Aubry A, Guilloux Y et al. (2008) MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med 205:2673-82
17. Hamburger AW (1987) The human tumor clonogenic assay as a model system in cell biology. Int J Cell Cloning 5:89-107 (Pubitemid 17045091)
18. Hoashi T, Watabe H, Muller J et al. (2005) MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes. J Biol Chem 280:14006-16 (Pubitemid 40517302)
19. Hodi FS, O'Day SJ, McDermott DF et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-23
20. Inoue K, Aoi N, Sato T et al. (2009) Differential expression of stem-cell-associated markers in human hair follicle epithelial cells. Lab Invest 89:844-56
21. Jemal A, Siegel R, Xu J et al. (2010) Cancer statistics. CA Cancer J Clin 60:277-300
22. Johnson LA, Morgan RA, Dudley ME et al. (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535-46
23. Kawakami Y, Eliyahu S, Delgado CH et al. (1994a) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91:3515-9 (Pubitemid 24139460)
24. Kawakami Y, Eliyahu S, Delgado CH et al. (1994b) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458-62
25. Maeurer MJ, Gollin SM, Martin D et al. (1996) Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 98:1633-41 (Pubitemid 26327874)
26. Peng PD, Cohen CJ, Yang S et al. (2009) Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther 16:1042-9
27. Quintana E, Shackleton M, Foster HR et al. (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18:510-23
28. Quintana E, Shackleton M, Sabel MS et al. (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593-8
29. Rasmusson I, Uhlin M, Le Blanc K et al. (2007) Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol 82:887-93 (Pubitemid 47511049)
30. Robbins PF, Dudley ME, Wunderlich J et al. (2004) Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173:7125-30 (Pubitemid 39628146)
31. Roesch A, Fukunaga-Kalabis M, Schmidt EC et al. (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141:583-94
32. Rosenberg SA, Dudley ME (2004) Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 101(Suppl 2):14639-45 (Pubitemid 39346736)
33. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233-40
34. Schatton T, Schutte U, Frank NY et al. (2010) Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res 70:697-708
35. Schmid DA, Irving MB, Posevitz V et al. (2010) Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 184:4936-46
36. Ueno T, Tomiyama H, Fujiwara M et al. (2004) Functionally impaired HIV-specific CD8 T cells show high affinity TCR-ligand interactions. J Immunol 173:5451-7 (Pubitemid 39392129)
37. Van Der Bruggen P, Traversari C, Chomez P et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-7 (Pubitemid 21917508)
38. Van Dinten LC, Pul N, van Nieuwpoort AF et al. (2005) Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens. Invest Ophthalmol Vis Sci 46:24-30 (Pubitemid 40041175)
39. Von Euw EM, Barrio MM, Furman D et al. (2007) Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8+ T lymphocytes. J Transl Med 5:19
40. Von Euw EM, Barrio MM, Furman D et al. (2008) A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10-1082 promoter genotype as predictor of disease progression. J Transl Med 6:6
41. Wang RF, Appella E, Kawakami Y et al. (1996) Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184:2207-16 (Pubitemid 27023721)
42. Williams BA, Wang XH, Keating A (2010) Clonogenic assays measure leukemia stem cell killing not detectable by chromium release and flow cytometric cytotoxicity assays. Cytotherapy 12:951-60
43. Yee C, Thompson JA, Byrd D et al. (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99:16168-73 (Pubitemid 35462767)